Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OpGen, Inc.    OPGN

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

OPGEN INC : Results of Operations and Financial Condition, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

05/07/2020 | 04:47pm EST

Item 2.02 Results of Operations and Financial Condition.

On May 7, 2020, OpGen, Inc. (the "Company") issued a press release announcing its first quarter financial results for the quarter ended March 31, 2020. The full text of such press release is furnished as Exhibit 99.1 to this report.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 6, 2020, the Board of Directors of the Company (the "Board") adopted revisions to the cash portion of its non-employee director compensation plan (as amended, the "Plan") for providing cash compensation to its non-employee directors for their service on the Board and its committees. The principal changes are to provide an annual retainer for the Chair of the Board in an amount of $75,000 and to provide certain adjustments to the retainers for committee chairs and committee members. The equity compensation portion of the Plan remains unchanged. The following table presents the revised annual cash retainers payable to non-employee directors under the Plan:



               Non-employee director (other than chair):   $ 25,000
               Board Chair:                                $ 75,000
               Audit Committee member:                     $  7,000
               Audit Committee Chair:                      $ 15,000
               Compensation Committee member:              $  6,000
               Compensation Committee Chair:               $ 12,000
               All other committee membership:             $  3,500
               All other committee Chair:                  $  7,500

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits


99.1 Press Release, dated May 7, 2020

The information included herein and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 ("Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

© Edgar Online, source Glimpses

All news about OPGEN, INC.
12/01OPGEN : Corporate Presentation (PDF)
PU
12/01OpGen Group Company Ares Genetics Advances ares-genetics.cloud Platform, Pres..
GL
11/24OPGEN INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equ..
AQ
11/24OPGEN : Announces $10 Million Private Placement Priced at the Market
AQ
11/24OpGen, Inc. Announces $10 Million Private Placement Priced at the Market
GL
11/16OPGEN : Note 2 - Liquidity and management's plans
AQ
11/13OPGEN : Corporate Presentation (PDF)
PU
11/13OPGEN INC : Entry into a Material Definitive Agreement, Other Events, Financial ..
AQ
11/12OPGEN : Ares Genetics Commercially Launches NGS-based Antibiotic Resistance Test..
AQ
11/12OpGen Group Company Ares Genetics Commercially Launches NGS-based Antibiotic ..
GL
More news
Financials (USD)
Sales 2020 4,12 M - -
Net income 2020 -26,4 M - -
Net Debt 2020 14,6 M - -
P/E ratio 2020 -1,16x
Yield 2020 -
Capitalization 44,3 M 44,3 M -
EV / Sales 2020 14,3x
EV / Sales 2021 7,36x
Nbr of Employees 39
Free-Float 99,9%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 5,33 $
Last Close Price 1,97 $
Spread / Highest target 187%
Spread / Average Target 170%
Spread / Lowest Target 154%
EPS Revisions
Managers
NameTitle
Oliver Schacht Chief Executive Officer & Director
Bill E. Rhodes Non-Executive Chairman
Johannes Bacher Chief Operating Officer
Timothy C. Dec CFO, Secretary & Chief Accounting Officer
Vadim Sapiro Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
OPGEN, INC.76.11%44
MODERNA, INC.705.88%56 587
LONZA GROUP AG56.34%45 782
CELLTRION, INC.93.92%42 101
IQVIA HOLDINGS INC.8.49%32 601
SEAGEN INC.57.68%31 921